SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company's programs and outlook at the following March conferences:

• Cowen & Company 34^th Annual Healthcare Conference at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 5, 2014 at 8:00 a.m. EST.
• 26^th Annual ROTH Conference at the Ritz-Carlton Laguna Niguel, CA on Monday, March 10, 2014 at 5:00 p.m. PDT.
• Alliance for Regenerative Medicine (ARM) 2^nd Annual Regen Med Investor Day at the Metropolitan Club in New York, NY, on Wednesday, March 26, 2014 at 1:00 p.m. EDT.

Live webcasts for each event can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. Archived replays of webcasts will be available on the Company's website for 30 days after each conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain hematologic malignancies, lysosomal storage disorders and muscular dystrophies. The Company utilizes established pharmacologic modalities, including small molecules and therapeutic proteins, and well-characterized biological mechanisms to enhance the therapeutic potential of adult stem cells. The Company has built two adult stem cell modulation platforms: a hematopoietic stem cell (HSC) modulation platform, which seeks to optimize the therapeutic potential of HSCs for treating patients with hematologic malignancies and rare genetic disorders that are undergoing hematopoietic stem cell transplantation, and a muscle satellite stem cell modulation platform, which seeks to activate the regenerative capacity of muscle for treating patients with degenerative muscle disorders. The Company is presently advancing its lead product candidate, ProHema®, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood, in which is in Phase 2 clinical development for hematologic malignancies. Fate Therapeutics is also advancing its proprietary Wnt7a protein analogs in preclinical development for the treatment of muscular dystrophies. Fate Therapeutics is headquartered in San Diego, CA.   For more information, please visit www.fatetherapeutics.com.

CONTACT: Paul Cox, Stern Investor Relations, Inc.

         212.362.1200, paul@sternir.com

News Provided by Acquire Media